Gastrointestinal haemorrhage in atrial fibrillation patients: Impact of quality of anticoagulation control

European Heart Journal - Cardiovascular Pharmacotherapy

Volumn 1, Issue 4, 2015, Pages 265-272

  Chan, Pak Hei ^a   Li, Wen Hua ^a   Hai, Jo Jo ^a   Chan, Koon Ho ^a   Tse, Hung Fat ^a   Cheung, Bernard Man Yung ^a   Chan, Esther W ^a   Wong, Ian C K ^a   Leung, Wai Keung ^a   Hung, Ivan Fan Ngai ^a   Lip, Gregory Y H ^b   Siu, Chung Wah ^a  

^a UNIVERSITY OF HONG KONG   (Hong Kong)

^b UNIVERSITY OF BIRMINGHAM   (United Kingdom)

Author keywords

Atrial fibrillation; Gastrointestinal haemorrhage; Time in therapeutic range

Indexed keywords

ACETYLSALICYLIC ACID; WARFARIN; ANTICOAGULANT AGENT;

AGED; ANTICOAGULATION; ARTICLE; ATRIAL FIBRILLATION; BLOOD TRANSFUSION; BRAIN ISCHEMIA; CHA2DS2-VASC SCORE; CHINESE; CONTROLLED STUDY; FEMALE; GASTROINTESTINAL HEMORRHAGE; HUMAN; INCIDENCE; MAJOR CLINICAL STUDY; MALE; MORTALITY; OBSERVATIONAL STUDY; PRIORITY JOURNAL; RISK ASSESSMENT; SCORING SYSTEM; VERY ELDERLY; CEREBROVASCULAR ACCIDENT; CHEMICALLY INDUCED; CHINA; COMPLICATION; FIBRINOLYTIC THERAPY; PROGNOSIS; RETROSPECTIVE STUDY;

AGED; ANTICOAGULANTS; ATRIAL FIBRILLATION; CHINA; FEMALE; GASTROINTESTINAL HEMORRHAGE; HUMANS; INCIDENCE; MALE; PROGNOSIS; RETROSPECTIVE STUDIES; STROKE; THROMBOLYTIC THERAPY;

EID: 84988815245     PISSN: 20556837     EISSN: 20556845     Source Type: Journal    
DOI: 10.1093/ehjcvp/pvv032     Document Type: Article

References (40)

1. Lip GY, Tse HF, Lane DA. Atrial fibrillation. Lancet 2012;379:648-661.
2. Camm AJ, Lip GY, De Caterina R, Savelieva I, Atar D, Hohnloser SH, Hindricks G, Kirchhof P; ESC Committee for Practice Guidelines-CPG; Document Reviewers. 2012 focused update of the ESC guidelines for the management of atrial fibrillation: An update of the 2010 ESC guidelines for the management of atrial fibrillation- developed with the special contribution of the European Heart Rhythm Association. Europace 2012;14:1385-1413.
3. Hart RG, Pearce LA, Aguilar MI. Adjusted-dose warfarin versus aspirin for preventing stroke in patients with atrial fibrillation. Ann Intern Med 2007;147:590-592.
4. Kakkar AK, Mueller I, Bassand JP, Fitzmaurice DA, Goldhaber SZ, Goto S, Haas S, HackeW, Lip GY, Mantovani LG, Turpie AG, van Eickels M, Misselwitz F, Rushton- Smith S, Kayani G, Wilkinson P, Verheugt FW. Risk profiles and antithrombotic treatment of patients newly diagnosed with atrial fibrillation at risk of stroke: perspectives from the international, observational, prospective GARFIELD registry. PLoS ONE 2013;8:e63479.
5. Oldgren J, Healey JS, Ezekowitz M, Commerford P, Avezum A, Pais P, Zhu J, Jansky P, Sigamani A, Morillo CA, Liu L, Damasceno A, Grinvalds A, Nakamya J, Reilly PA, Keltai K, Van Gelder IC, Yusufali AH, Watanabe E, Wallentin L, Connolly SJ, Yusuf S. Variations in cause and management of atrial fibrillation in a prospective registry of 15, 400 emergency department patients in 46 countries: The RE-LY atrial fibrillation registry. Circulation 2014;129:1568-1576.
6. Chien KL, Su TC, Hsu HC, Chang WT, Chen PC, Chen MF, Lee YT. Atrial fibrillation prevalence, incidence and risk of stroke and all-cause death among chinese. Int J Cardiol 2010;139:173-180.
7. Lin LY, Lee CH, Yu CC, Tsai CT, Lai LP, Hwang JJ, Chen PC, Lin JL. Risk factors and incidence of ischemic stroke in Taiwanese with nonvalvular atrial fibrillation-A nationwide database analysis. Atherosclerosis 2011;217:292-295.
8. Zhang LF, Yang J, Hong Z, Yuan GG, Zhou BF, Zhao LC, Huang YN, Chen J, Wu YF; Collaborative Group of China Multicenter Study of Cardiovascular Epidemiology. Proportion of different subtypes of stroke in china. Stroke 2003;34:2091-2096.
9. Huang CY, Chan FL, Yu YL, Woo E, Chin D. Cerebrovascular disease in hong kong chinese. Stroke 1990;21:230-235.
10. Yang QD, Niu Q, Zhou YH, Liu YH, Xu HW, Gu WP, Tian FF, Xie YQ, Zhang L, Xia J. Incidence of cerebral hemorrhage in the Changsha community. A prospective study from 1986 to 2000. Cerebrovasc Dis 2004;17:303-313.
11. Chiang CE, Wang KL, Lip GY. Stroke prevention in atrial fibrillation: An Asian perspective. Thromb Haemost 2014;111:789-797.
12. Camm AJ, Lip GY, De Caterina R, Savelieva I, Atar D, Hohnloser SH, Hindricks G, Kirchhof P; ESC Committee for Practice Guidelines (CPG). 2012 focused update of the ESC guidelines for the management of atrial fibrillation: An update of the 2010 ESC guidelines for the management of atrial fibrillation. Developed with the special contribution of the European Heart Rhythm Association. Eur Heart J 2012;33: 2719-2747.
13. Huang D, Anguo L, Yue WS, Yin L, Tse HF, Siu CW. Refinement of ischemic stroke risk in patients with atrial fibrillation and CHA2DS2-VASc score of 1. Pacing Clin Electrophysiol 2014;37:1442-1447.
14. Li SY, Zhao XQ, Wang CX, Liu LP, Liu GF, Wang YL, Wang YJ. One-year clinical prediction in Chinese ischemic stroke patients using the CHA2DS2 and CHA2DS2- VASc scores: The China National Stroke registry. CNS Neurosci Ther 2012;18: 988-993.
15. Siu CW, Lip GY, Lam KF, Tse HF. Risk of stroke and intracranial hemorrhage in 9727 Chinese with atrial fibrillation in Hong Kong. Heart Rhythm 2014;11: 1401-1408.
16. Siu CW, Tse HF. Net clinical benefit of warfarin therapy in elderly Chinese patients with atrial fibrillation. Circ Arrhythm Electrophysiol 2014;7:300-306.
17. Chan KH, Ka-Kit Leung G, Lau KK, Liu S, Lui WM, Lau CP, Tse HF, Kan-Suen Pu J, Siu CW. Predictive value of the HAS-BLED score for the risk of recurrent intracranial hemorrhage after first spontaneous intracranial hemorrhage. World Neurosurg 2014;82:e219-e223.
18. Chong BH, Chan KH, Pong V, Lau KK, Chan YH, Zuo ML, Lui WM, Leung GK, Lau CP, Tse HF, Pu JK, Siu CW. Use of aspirin in Chinese after recovery from primary intracranial haemorrhage. Thromb Haemost 2012;107:241-247.
19. Teo KC, Mahboobani NR, Lee R, Siu CW, Cheung RT, Ho SL, Lau KK, Chan KH. Warfarin associated intracerebral hemorrhage in Hong Kong Chinese. Neurol Res 2014;36:143-149.
20. Pong V, Chan KH, Chong BH, Lui WM, Leung GK, Tse HF, Pu JK, Siu CW. Longterm outcome and prognostic factors after spontaneous cerebellar hemorrhage. Cerebellum 2012;11:939-945.
21. Choudari CP, Palmer KR. Acute gastrointestinal haemorrhage in patients treated with anticoagulant drugs. Gut 1995;36:483-484.
22. Coleman CI, Sobieraj DM, Winkler S, Cutting P, Mediouni M, Alikhanov S, Kluger J. Effect of pharmacological therapies for stroke prevention on major gastrointestinal bleeding in patients with atrial fibrillation. Int J Clin Pract 2012;66:53-63.
23. Connolly SJ, Pogue J, Eikelboom J, Flaker G, Commerford P, Franzosi MG, Healey JS, Yusuf S; ACTIVE W Investigators. Benefit of oral anticoagulant over antiplatelet therapy in atrial fibrillation depends on the quality of international normalized ratio control achieved by centers and countries as measured by time in therapeutic range. Circulation 2008;118:2029-2037.
24. White HD, Gruber M, Feyzi J, Kaatz S, Tse HF, Husted S, Albers GW. Comparison of outcomes among patients randomized to warfarin therapy according to anticoagulant control: Results from SPORTIF III and V. Arch Intern Med 2007;167: 239-245.
25. Wan Y, Heneghan C, Perera R, Roberts N, Hollowell J, Glasziou P, Bankhead C, Xu Y. Anticoagulation control and prediction of adverse events in patients with atrial fibrillation: A systematic review. Circ Cardiovasc Qual Outcomes 2008;1:84-91.
26. Ho CW, Ho MH, Chan PH, Hai JJ, Cheung E, Yeung CY, Lau KK, Chan KH, Lau CP, Lip GY, Leung GK, Tse HF, Siu CW. Ischemic stroke and intracranial hemorrhage with aspirin, dabigatran, and warfarin: impact of quality of anticoagulation control. Stroke 2015;46:23-30.
27. Gallego P, Roldan V, Marin F, Romera M, Valdes M, Vicente V, Lip GY. Cessation of oral anticoagulation in relation to mortality and the risk of thrombotic events in patients with atrial fibrillation. Thromb Haemost 2013;110:1189-1198.
28. Rosendaal FR, Cannegieter SC, van der Meer FJ, Briet E. A method to determine the optimal intensity of oral anticoagulant therapy. Thromb Haemost 1993;69:236-239.
29. Qureshi W, Mittal C, Patsias I, Garikapati K, Kuchipudi A, Cheema G, Elbatta M, Alirhayim Z, Khalid F. Restarting anticoagulation and outcomes after major gastrointestinal bleeding in atrial fibrillation. Am J Cardiol 2014;113:662-668.
30. Lee JK, Kang HW, Kim SG, Kim JS, Jung HC. Risks related with withholding and resuming anticoagulation in patients with non-variceal upper gastrointestinal bleeding while on warfarin therapy. Int J Clin Pract 2012;66:64-68.
31. Raunso J, Selmer C, Olesen JB, Charlot MG, Olsen AM, Bretler DM, Nielsen JD, Dominguez H, Gadsboll N, Kober L, Gislason GH, Torp-Pedersen C, Hansen ML. Increased short-Term risk of thrombo-embolism or death after interruption of warfarin treatment in patients with atrial fibrillation. Eur Heart J 2012;33: 1886-1892.
32. Petersen P, Boysen G, Godtfredsen J, Andersen ED, Andersen B. Placebocontrolled, randomised trial of warfarin and aspirin for prevention of thromboembolic complications in chronic atrial fibrillation. The Copenhagen AFASAK study. Lancet 1989;1:175-179.
33. Sam C, Massaro JM, D'Agostino RB Sr, Levy D, Lambert JW, Wolf PA, Benjamin EJ; Framingham Heart Study. Warfarin and aspirin use and the predictors of major bleeding complications in atrial fibrillation (the Framingham Heart Study). Am J Cardiol 2004;94:947-951.
34. Yeomans ND, Lanas AI, Talley NJ, Thomson AB, Daneshjoo R, Eriksson B, Appelman- Eszczuk S, Langstrom G, Naesdal J, Serrano P, Singh M, Skelly MM, Hawkey CJ. Prevalence and incidence of gastroduodenal ulcers during treatment with vascular protective doses of aspirin. Aliment Pharmacol Ther 2005;22:795-801.
35. Lip GY, Andreotti F, Fauchier L, Huber K, Hylek E, Knight E, Lane DA, Levi M, Marin F, Palareti G, Kirchhof P, Document R, Collet JP, Rubboli A, Poli D, Camm J. Bleeding risk assessment and management in atrial fibrillation patients: A position document from the European Heart Rhythm Association, endorsed by the European Society of Cardiology working group on thrombosis. Europace 2011;13: 723-746.
36. Sabir I, Khavandi K, Brownrigg J, Camm AJ. Oral anticoagulants for Asian patients with atrial fibrillation. Nat Rev Cardiol 2014;11:290-303.
37. Hori M, Connolly SJ, Zhu J, Liu LS, Lau CP, Pais P, Xavier D, Kim SS, Omar R, Dans AL, Tan RS, Chen JH, Tanomsup S, Watanabe M, Koyanagi M, Ezekowitz MD, Reilly PA, Wallentin L, Yusuf S; RE-LY Investigators. Dabigatran versus warfarin: Effects on ischemic and hemorrhagic strokes and bleeding in Asians and non-Asians with atrial fibrillation. Stroke 2013;44:1891-1896.
38. Ashburner JM, Go AS, Reynolds K, Chang Y, Fang MC, Fredman L, Applebaum KM, Singer DE. Comparison of frequency and outcome of major gastrointestinal hemorrhage in patients with atrial fibrillation on versus not receiving warfarin therapy (from the atria and atria-CVRN cohorts). Am J Cardiol 2015;115:40-46.
39. Sengupta N, Feuerstein JD, Patwardhan VR, Tapper EB, Ketwaroo GA, Thaker AM, Leffler DA. The risks of thromboembolism vs. recurrent gastrointestinal bleeding after interruption of systemic anticoagulation in hospitalized inpatients with gastrointestinal bleeding: A prospective study. Am J Gastroenterol 2015;110:328-335.
40. Hsiao F-Y, Tsai Y-W, Huang W-F, Wen Y-W, Chen P-F, Chang P-Y, Kuo KN. A comparison of aspirin and clopidogrel with or without proton pump inhibitors for the secondary prevention of cardiovascular events in patients at high risk for gastrointestinal bleeding. Clin Ther 2009;31:2038-2047.